BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Momcilovic M, Bailey ST, Lee JT, Fishbein MC, Magyar C, Braas D, Graeber T, Jackson NJ, Czernin J, Emberley E, Gross M, Janes J, Mackinnon A, Pan A, Rodriguez M, Works M, Zhang W, Parlati F, Demo S, Garon E, Krysan K, Walser TC, Dubinett SM, Sadeghi S, Christofk HR, Shackelford DB. Targeted Inhibition of EGFR and Glutaminase Induces Metabolic Crisis in EGFR Mutant Lung Cancer. Cell Rep 2017;18:601-10. [PMID: 28099841 DOI: 10.1016/j.celrep.2016.12.061] [Cited by in Crossref: 80] [Cited by in F6Publishing: 75] [Article Influence: 16.0] [Reference Citation Analysis]
Number Citing Articles
1 Sarkis J, Sarkis P, Alkassis M, Assaf J, Ghazi R. Novel targets for refractory kidney cancer: Where are we heading? J Oncol Pharm Pract 2021;27:1559-61. [PMID: 34162246 DOI: 10.1177/10781552211027216] [Reference Citation Analysis]
2 Sheikh TN, Patwardhan PP, Cremers S, Schwartz GK. Targeted inhibition of glutaminase as a potential new approach for the treatment of NF1 associated soft tissue malignancies. Oncotarget 2017;8:94054-68. [PMID: 29212209 DOI: 10.18632/oncotarget.21573] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
3 Galan-Cobo A, Sitthideatphaiboon P, Qu X, Poteete A, Pisegna MA, Tong P, Chen PH, Boroughs LK, Rodriguez MLM, Zhang W, Parlati F, Wang J, Gandhi V, Skoulidis F, DeBerardinis RJ, Minna JD, Heymach JV. LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in KRAS-Mutant Lung Adenocarcinoma. Cancer Res 2019;79:3251-67. [PMID: 31040157 DOI: 10.1158/0008-5472.CAN-18-3527] [Cited by in Crossref: 65] [Cited by in F6Publishing: 41] [Article Influence: 21.7] [Reference Citation Analysis]
4 Xia M, Li X, Diao Y, Du B, Li Y. Targeted inhibition of glutamine metabolism enhances the antitumor effect of selumetinib in KRAS-mutant NSCLC. Transl Oncol 2021;14:100920. [PMID: 33137541 DOI: 10.1016/j.tranon.2020.100920] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Soomro I, Sun Y, Li Z, Diggs L, Hatzivassiliou G, Thomas AG, Rais R, Parker SJ, Slusher BS, Kimmelman AC, Somlo S, Skolnik EY. Glutamine metabolism via glutaminase 1 in autosomal-dominant polycystic kidney disease. Nephrol Dial Transplant 2018;33:1343-53. [PMID: 29420817 DOI: 10.1093/ndt/gfx349] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
6 Méndez-Lucas A, Lin W, Driscoll PC, Legrave N, Novellasdemunt L, Xie C, Charles M, Wilson Z, Jones NP, Rayport S, Rodríguez-Justo M, Li V, MacRae JI, Hay N, Chen X, Yuneva M. Identifying strategies to target the metabolic flexibility of tumours. Nat Metab 2020;2:335-50. [PMID: 32694609 DOI: 10.1038/s42255-020-0195-8] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 11.5] [Reference Citation Analysis]
7 Meng M, Geng S, Du Z, Yao J, Zheng Y, Li Z, Zhang Z, Li J, Duan Y, Du G. Berberine and cinnamaldehyde together prevent lung carcinogenesis. Oncotarget 2017;8:76385-97. [PMID: 29100319 DOI: 10.18632/oncotarget.20059] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
8 Shah R, Singh SJ, Eddy K, Filipp FV, Chen S. Concurrent Targeting of Glutaminolysis and Metabotropic Glutamate Receptor 1 (GRM1) Reduces Glutamate Bioavailability in GRM1+ Melanoma. Cancer Res 2019;79:1799-809. [PMID: 30987979 DOI: 10.1158/0008-5472.CAN-18-1500] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 4.7] [Reference Citation Analysis]
9 Elbanna M, Chowdhury NN, Rhome R, Fishel ML. Clinical and Preclinical Outcomes of Combining Targeted Therapy With Radiotherapy. Front Oncol 2021;11:749496. [PMID: 34733787 DOI: 10.3389/fonc.2021.749496] [Reference Citation Analysis]
10 Saha SK, Islam SMR, Abdullah-Al-Wadud M, Islam S, Ali F, Park KS. Multiomics Analysis Reveals that GLS and GLS2 Differentially Modulate the Clinical Outcomes of Cancer. J Clin Med 2019;8:E355. [PMID: 30871151 DOI: 10.3390/jcm8030355] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
11 Tee SS, Park JM, Hurd RE, Brimacombe KR, Boxer MB, Massoud TF, Rutt BK, Spielman DM. PKM2 activation sensitizes cancer cells to growth inhibition by 2-deoxy-D-glucose. Oncotarget 2017;8:90959-68. [PMID: 29207616 DOI: 10.18632/oncotarget.19630] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
12 Whi W, Ha S, Bae S, Choi H, Paeng JC, Cheon GJ, Kang KW, Lee DS. Relationship of EGFR Mutation to Glucose Metabolic Activity and Asphericity of Metabolic Tumor Volume in Lung Adenocarcinoma. Nucl Med Mol Imaging 2020;54:175-82. [PMID: 32831963 DOI: 10.1007/s13139-020-00646-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Fung MKL, Chan GC. Drug-induced amino acid deprivation as strategy for cancer therapy. J Hematol Oncol 2017;10:144. [PMID: 28750681 DOI: 10.1186/s13045-017-0509-9] [Cited by in Crossref: 58] [Cited by in F6Publishing: 56] [Article Influence: 11.6] [Reference Citation Analysis]
14 Pham-Danis C, Gehrke S, Danis E, Rozhok AI, Daniels MW, Gao D, Collins C, Paola JTD, D'Alessandro A, DeGregori J. Urea Cycle Sustains Cellular Energetics upon EGFR Inhibition in EGFR-Mutant NSCLC. Mol Cancer Res 2019;17:1351-64. [PMID: 30808730 DOI: 10.1158/1541-7786.MCR-18-1068] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
15 Majem B, Nadal E, Muñoz-Pinedo C. Exploiting metabolic vulnerabilities of Non small cell lung carcinoma. Semin Cell Dev Biol 2020;98:54-62. [PMID: 31238096 DOI: 10.1016/j.semcdb.2019.06.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
16 Lo YC, Liu T, Morrissey KM, Kakiuchi-Kiyota S, Johnson AR, Broccatelli F, Zhong Y, Joshi A, Altman RB. Computational analysis of kinase inhibitor selectivity using structural knowledge. Bioinformatics 2019;35:235-42. [PMID: 29985971 DOI: 10.1093/bioinformatics/bty582] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
17 Fukano M, Park M, Deblois G. Metabolic Flexibility Is a Determinant of Breast Cancer Heterogeneity and Progression. Cancers (Basel) 2021;13:4699. [PMID: 34572926 DOI: 10.3390/cancers13184699] [Reference Citation Analysis]
18 Seth Nanda C, Venkateswaran SV, Patani N, Yuneva M. Defining a metabolic landscape of tumours: genome meets metabolism. Br J Cancer 2020;122:136-49. [PMID: 31819196 DOI: 10.1038/s41416-019-0663-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
19 Allen E, Missiaen R, Bergers G. Trimming the Vascular Tree in Tumors: Metabolic and Immune Adaptations. Cold Spring Harb Symp Quant Biol 2016;81:21-9. [PMID: 28396525 DOI: 10.1101/sqb.2016.81.030940] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
20 Queiroz AL, Vakifahmetoglu-Norberg H, Norberg E. Resistant to Targeted Therapy - Aim for Metabolic Liabilities. Theranostics 2018;8:2061-3. [PMID: 29569651 DOI: 10.7150/thno.24454] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
21 Meijer TWH, Looijen-Salamon MG, Lok J, van den Heuvel M, Tops B, Kaanders JHAM, Span PN, Bussink J. Glucose and glutamine metabolism in relation to mutational status in NSCLC histological subtypes. Thorac Cancer 2019;10:2289-99. [PMID: 31668020 DOI: 10.1111/1759-7714.13226] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
22 Reis LMD, Adamoski D, Ornitz Oliveira Souza R, Rodrigues Ascenção CF, Sousa de Oliveira KR, Corrêa-da-Silva F, Malta de Sá Patroni F, Meira Dias M, Consonni SR, Mendes de Moraes-Vieira PM, Silber AM, Dias SMG. Dual inhibition of glutaminase and carnitine palmitoyltransferase decreases growth and migration of glutaminase inhibition-resistant triple-negative breast cancer cells. J Biol Chem 2019;294:9342-57. [PMID: 31040181 DOI: 10.1074/jbc.RA119.008180] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
23 Ge J, Cui H, Xie N, Banerjee S, Guo S, Dubey S, Barnes S, Liu G. Glutaminolysis Promotes Collagen Translation and Stability via α-Ketoglutarate-mediated mTOR Activation and Proline Hydroxylation. Am J Respir Cell Mol Biol 2018;58:378-90. [PMID: 29019707 DOI: 10.1165/rcmb.2017-0238OC] [Cited by in Crossref: 41] [Cited by in F6Publishing: 26] [Article Influence: 10.3] [Reference Citation Analysis]
24 Shen YA, Chen CL, Huang YH, Evans EE, Cheng CC, Chuang YJ, Zhang C, Le A. Inhibition of glutaminolysis in combination with other therapies to improve cancer treatment. Curr Opin Chem Biol 2021;62:64-81. [PMID: 33721588 DOI: 10.1016/j.cbpa.2021.01.006] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
25 Kurmi K, Haigis MC. Nitrogen Metabolism in Cancer and Immunity. Trends Cell Biol. 2020;30:408-424. [PMID: 32302552 DOI: 10.1016/j.tcb.2020.02.005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
26 Zhao Y, Feng X, Chen Y, Selfridge JE, Gorityala S, Du Z, Wang JM, Hao Y, Cioffi G, Conlon RA, Barnholtz-Sloan JS, Saltzman J, Krishnamurthi SS, Vinayak S, Veigl M, Xu Y, Bajor DL, Markowitz SD, Meropol NJ, Eads JR, Wang Z. 5-Fluorouracil Enhances the Antitumor Activity of the Glutaminase Inhibitor CB-839 against PIK3CA-Mutant Colorectal Cancers. Cancer Res 2020;80:4815-27. [PMID: 32907836 DOI: 10.1158/0008-5472.CAN-20-0600] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
27 Cohen AS, Geng L, Zhao P, Fu A, Schulte ML, Graves-Deal R, Washington MK, Berlin J, Coffey RJ, Manning HC. Combined blockade of EGFR and glutamine metabolism in preclinical models of colorectal cancer. Transl Oncol 2020;13:100828. [PMID: 32652471 DOI: 10.1016/j.tranon.2020.100828] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
28 Zhang J, Mao S, Guo Y, Wu Y, Yao X, Huang Y. Inhibition of GLS suppresses proliferation and promotes apoptosis in prostate cancer. Biosci Rep 2019;39:BSR20181826. [PMID: 31196962 DOI: 10.1042/BSR20181826] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
29 Cheng ZJ, Miao DL, Su QY, Tang XL, Wang XL, Deng LB, Shi HD, Xin HB. THZ1 suppresses human non-small-cell lung cancer cells in vitro through interference with cancer metabolism. Acta Pharmacol Sin 2019;40:814-22. [PMID: 30446732 DOI: 10.1038/s41401-018-0187-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
30 Kunos CA. Novel Radiosensitization Strategies in Uterine Cervix Cancer. Semin Radiat Oncol 2020;30:281-90. [PMID: 32828384 DOI: 10.1016/j.semradonc.2020.05.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Kochanowski K, Sander T, Link H, Chang J, Altschuler SJ, Wu LF. Systematic alteration of in vitro metabolic environments reveals empirical growth relationships in cancer cell phenotypes. Cell Rep 2021;34:108647. [PMID: 33472066 DOI: 10.1016/j.celrep.2020.108647] [Reference Citation Analysis]
32 Poliaková M, Aebersold DM, Zimmer Y, Medová M. The relevance of tyrosine kinase inhibitors for global metabolic pathways in cancer. Mol Cancer 2018;17:27. [PMID: 29455660 DOI: 10.1186/s12943-018-0798-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
33 Emberley E, Pan A, Chen J, Dang R, Gross M, Huang T, Li W, MacKinnon A, Singh D, Sotirovska N, Steggerda SM, Wang T, Parlati F. The glutaminase inhibitor telaglenastat enhances the antitumor activity of signal transduction inhibitors everolimus and cabozantinib in models of renal cell carcinoma. PLoS One 2021;16:e0259241. [PMID: 34731180 DOI: 10.1371/journal.pone.0259241] [Reference Citation Analysis]
34 Ruiz-Rodado V, Lita A, Dowdy T, Celiku O, Saldana AC, Wang H, Yang CZ, Chari R, Li A, Zhang W, Song H, Zhang M, Ahn S, Davis D, Chen X, Zhuang Z, Herold-Mende C, Walters KJ, Gilbert MR, Larion M. Metabolic plasticity of IDH1-mutant glioma cell lines is responsible for low sensitivity to glutaminase inhibition. Cancer Metab 2020;8:23. [PMID: 33101674 DOI: 10.1186/s40170-020-00229-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
35 Ito A, Nasako H, Akizuki R, Takashina Y, Eguchi H, Matsunaga T, Yoshino Y, Endo S, Ikari A. Elevation of Chemosensitivity of Lung Adenocarcinoma A549 Spheroid Cells by Claudin-2 Knockdown through Activation of Glucose Transport and Inhibition of Nrf2 Signal. Int J Mol Sci 2021;22:6582. [PMID: 34205320 DOI: 10.3390/ijms22126582] [Reference Citation Analysis]
36 Iradyan M, Iradyan N, Hulin P, Hambardzumyan A, Gyulkhandanyan A, Alves de Sousa R, Hessani A, Roussakis C, Bollot G, Bauvais C, Sakanyan V. Targeting Degradation of EGFR through the Allosteric Site Leads to Cancer Cell Detachment-Promoted Death. Cancers (Basel) 2019;11:E1094. [PMID: 31374910 DOI: 10.3390/cancers11081094] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
37 Inoue J, Fujiwara K, Hamamoto H, Kobayashi K, Inazawa J. Improving the Efficacy of EGFR Inhibitors by Topical Treatment of Cutaneous Squamous Cell Carcinoma with miR-634 Ointment. Mol Ther Oncolytics 2020;19:294-307. [PMID: 33294587 DOI: 10.1016/j.omto.2020.10.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
38 Xu X, Meng Y, Li L, Xu P, Wang J, Li Z, Bian J. Overview of the Development of Glutaminase Inhibitors: Achievements and Future Directions. J Med Chem 2019;62:1096-115. [PMID: 30148361 DOI: 10.1021/acs.jmedchem.8b00961] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 9.3] [Reference Citation Analysis]
39 Talukdar S, Emdad L, Das SK, Fisher PB. EGFR: An essential receptor tyrosine kinase-regulator of cancer stem cells. Adv Cancer Res 2020;147:161-88. [PMID: 32593400 DOI: 10.1016/bs.acr.2020.04.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
40 Daemen A, Liu B, Song K, Kwong M, Gao M, Hong R, Nannini M, Peterson D, Liederer BM, de la Cruz C, Sangaraju D, Jaochico A, Zhao X, Sandoval W, Hunsaker T, Firestein R, Latham S, Sampath D, Evangelista M, Hatzivassiliou G. Pan-Cancer Metabolic Signature Predicts Co-Dependency on Glutaminase and De Novo Glutathione Synthesis Linked to a High-Mesenchymal Cell State. Cell Metabolism 2018;28:383-399.e9. [DOI: 10.1016/j.cmet.2018.06.003] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 7.5] [Reference Citation Analysis]
41 Beatty A, Fink LS, Singh T, Strigun A, Peter E, Ferrer CM, Nicolas E, Cai KQ, Moran TP, Reginato MJ, Rennefahrt U, Peterson JR. Metabolite Profiling Reveals the Glutathione Biosynthetic Pathway as a Therapeutic Target in Triple-Negative Breast Cancer. Mol Cancer Ther 2018;17:264-75. [PMID: 29021292 DOI: 10.1158/1535-7163.MCT-17-0407] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 4.6] [Reference Citation Analysis]
42 Cargill KR, Hasken WL, Gay CM, Byers LA. Alternative Energy: Breaking Down the Diverse Metabolic Features of Lung Cancers. Front Oncol 2021;11:757323. [PMID: 34745994 DOI: 10.3389/fonc.2021.757323] [Reference Citation Analysis]
43 Wilder CS, Chen Z, DiGiovanni J. Pharmacologic approaches to amino acid depletion for cancer therapy. Mol Carcinog 2021. [PMID: 34534385 DOI: 10.1002/mc.23349] [Reference Citation Analysis]
44 Gregory MA, Nemkov T, Park HJ, Zaberezhnyy V, Gehrke S, Adane B, Jordan CT, Hansen KC, D'Alessandro A, DeGregori J. Targeting Glutamine Metabolism and Redox State for Leukemia Therapy. Clin Cancer Res. 2019;25:4079-4090. [PMID: 30940653 DOI: 10.1158/1078-0432.ccr-18-3223] [Cited by in Crossref: 40] [Cited by in F6Publishing: 22] [Article Influence: 13.3] [Reference Citation Analysis]
45 Xiao Y, Meierhofer D. Glutathione Metabolism in Renal Cell Carcinoma Progression and Implications for Therapies.Int J Mol Sci. 2019;20. [PMID: 31357507 DOI: 10.3390/ijms20153672] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 7.3] [Reference Citation Analysis]
46 Min HY, Lee HY. Oncogene-Driven Metabolic Alterations in Cancer. Biomol Ther (Seoul) 2018;26:45-56. [PMID: 29212306 DOI: 10.4062/biomolther.2017.211] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
47 Matés JM, Di Paola FJ, Campos-Sandoval JA, Mazurek S, Márquez J. Therapeutic targeting of glutaminolysis as an essential strategy to combat cancer. Semin Cell Dev Biol 2020;98:34-43. [PMID: 31100352 DOI: 10.1016/j.semcdb.2019.05.012] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 10.3] [Reference Citation Analysis]
48 Momcilovic M, Bailey ST, Lee JT, Zamilpa C, Jones A, Abdelhady G, Mansfield J, Francis KP, Shackelford DB. Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer. J Vis Exp 2018. [PMID: 30080208 DOI: 10.3791/57167] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
49 Shah R, Chen S. Metabolic Signaling Cascades Prompted by Glutaminolysis in Cancer. Cancers (Basel) 2020;12:E2624. [PMID: 32937954 DOI: 10.3390/cancers12092624] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
50 Kishikawa M, Inoue J, Hamamoto H, Kobayashi K, Asakage T, Inazawa J. Augmentation of lenvatinib efficacy by topical treatment of miR-634 ointment in anaplastic thyroid cancer. Biochem Biophys Rep 2021;26:101009. [PMID: 34027135 DOI: 10.1016/j.bbrep.2021.101009] [Reference Citation Analysis]
51 Bajpai R, Shanmugam M. Targeting cancer metabolism through synthetic lethality-based combinatorial treatment strategies. Curr Opin Oncol 2018;30:338-44. [PMID: 29994904 DOI: 10.1097/CCO.0000000000000467] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
52 Borne AL, Huang T, McCloud RL, Pachaiyappan B, Bullock TNJ, Hsu KL. Deciphering T Cell Immunometabolism with Activity-Based Protein Profiling. Curr Top Microbiol Immunol 2019;420:175-210. [PMID: 30128827 DOI: 10.1007/82_2018_124] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
53 Weyandt JD, Thompson CB, Giaccia AJ, Rathmell WK. Metabolic Alterations in Cancer and Their Potential as Therapeutic Targets. Am Soc Clin Oncol Educ Book 2017;37:825-32. [PMID: 28561705 DOI: 10.1200/EDBK_175561] [Cited by in Crossref: 16] [Article Influence: 3.2] [Reference Citation Analysis]
54 Possemato R. Minding the Ls and Qs. Nat Metab 2019;1:308-9. [PMID: 32694722 DOI: 10.1038/s42255-019-0046-7] [Reference Citation Analysis]
55 Momcilovic M, Shackelford DB. Imaging Cancer Metabolism. Biomol Ther (Seoul) 2018;26:81-92. [PMID: 29212309 DOI: 10.4062/biomolther.2017.220] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
56 Shen YA, Hong J, Asaka R, Asaka S, Hsu FC, Suryo Rahmanto Y, Jung JG, Chen YW, Yen TT, Tomaszewski A, Zhang C, Attarwala N, DeMarzo AM, Davidson B, Chuang CM, Chen X, Gaillard S, Le A, Shih IM, Wang TL. Inhibition of the MYC-Regulated Glutaminase Metabolic Axis Is an Effective Synthetic Lethal Approach for Treating Chemoresistant Ovarian Cancers. Cancer Res 2020;80:4514-26. [PMID: 32859605 DOI: 10.1158/0008-5472.CAN-19-3971] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
57 Sun C, Wang F, Wang X, Geng Y, Song S, Yu Z, Liu W. The choice of tissue fixative is a key determinant for mass spectrometry imaging based tumor metabolic reprogramming characterization. Anal Bioanal Chem 2020;412:3123-34. [PMID: 32236659 DOI: 10.1007/s00216-020-02562-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
58 Assali EA, Jones AE, Veliova M, Acín-Pérez R, Taha M, Miller N, Shum M, Oliveira MF, Las G, Liesa M, Sekler I, Shirihai OS. NCLX prevents cell death during adrenergic activation of the brown adipose tissue. Nat Commun 2020;11:3347. [PMID: 32620768 DOI: 10.1038/s41467-020-16572-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
59 Wang Z, Liu F, Fan N, Zhou C, Li D, Macvicar T, Dong Q, Bruns CJ, Zhao Y. Targeting Glutaminolysis: New Perspectives to Understand Cancer Development and Novel Strategies for Potential Target Therapies. Front Oncol 2020;10:589508. [PMID: 33194749 DOI: 10.3389/fonc.2020.589508] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
60 Szeliga M. Thiadiazole derivatives as anticancer agents. Pharmacol Rep 2020;72:1079-100. [PMID: 32880874 DOI: 10.1007/s43440-020-00154-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
61 Marengo B, Garbarino O, Speciale A, Monteleone L, Traverso N, Domenicotti C. MYC Expression and Metabolic Redox Changes in Cancer Cells: A Synergy Able to Induce Chemoresistance. Oxid Med Cell Longev 2019;2019:7346492. [PMID: 31341534 DOI: 10.1155/2019/7346492] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
62 Soth MJ, Le K, Di Francesco ME, Hamilton MM, Liu G, Burke JP, Carroll CL, Kovacs JJ, Bardenhagen JP, Bristow CA, Cardozo M, Czako B, de Stanchina E, Feng N, Garvey JR, Gay JP, Do MKG, Greer J, Han M, Harris A, Herrera Z, Huang S, Giuliani V, Jiang Y, Johnson SB, Johnson TA, Kang Z, Leonard PG, Liu Z, McAfoos T, Miller M, Morlacchi P, Mullinax RA, Palmer WS, Pang J, Rogers N, Rudin CM, Shepard HE, Spencer ND, Theroff J, Wu Q, Xu A, Yau JA, Draetta G, Toniatti C, Heffernan TP, Jones P. Discovery of IPN60090, a Clinical Stage Selective Glutaminase-1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties. J Med Chem 2020;63:12957-77. [PMID: 33118821 DOI: 10.1021/acs.jmedchem.0c01398] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
63 Lypova N, Telang S, Chesney J, Imbert-Fernandez Y. Increased 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 activity in response to EGFR signaling contributes to non-small cell lung cancer cell survival. J Biol Chem 2019;294:10530-43. [PMID: 31126985 DOI: 10.1074/jbc.RA119.007784] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
64 Weyandt JD, Thompson CB, Giaccia AJ, Rathmell WK. Metabolic Alterations in Cancer and Their Potential as Therapeutic Targets. Am Soc Clin Oncol Educ Book 2017;37:825-32. [PMID: 28561705 DOI: 10.1200/EDBK_175561] [Cited by in Crossref: 4] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
65 Hoerner CR, Miao SY, Hsieh JJ, Fan AC. Targeting Metabolic Pathways in Kidney Cancer: Rationale and Therapeutic Opportunities. Cancer J 2020;26:407-18. [PMID: 32947309 DOI: 10.1097/PPO.0000000000000472] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
66 Boysen G, Jamshidi-Parsian A, Davis MA, Siegel ER, Simecka CM, Kore RA, Dings RPM, Griffin RJ. Glutaminase inhibitor CB-839 increases radiation sensitivity of lung tumor cells and human lung tumor xenografts in mice. Int J Radiat Biol 2019;95:436-42. [PMID: 30557074 DOI: 10.1080/09553002.2018.1558299] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 12.0] [Reference Citation Analysis]
67 Hipólito A, Mendes C, Serpa J. The Metabolic Remodelling in Lung Cancer and Its Putative Consequence in Therapy Response. Adv Exp Med Biol 2020;1219:311-33. [PMID: 32130706 DOI: 10.1007/978-3-030-34025-4_16] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
68 Hoerner CR, Chen VJ, Fan AC. The 'Achilles Heel' of Metabolism in Renal Cell Carcinoma: Glutaminase Inhibition as a Rational Treatment Strategy. Kidney Cancer 2019;3:15-29. [PMID: 30854496 DOI: 10.3233/KCA-180043] [Cited by in Crossref: 26] [Cited by in F6Publishing: 14] [Article Influence: 8.7] [Reference Citation Analysis]
69 Chen CH, Wang BW, Hsiao YC, Wu CY, Cheng FJ, Hsia TC, Chen CY, Wang Y, Weihua Z, Chou RH, Tang CH, Chen YJ, Wei YL, Hsu JL, Tu CY, Hung MC, Huang WC. PKCδ-mediated SGLT1 upregulation confers the acquired resistance of NSCLC to EGFR TKIs. Oncogene 2021;40:4796-808. [PMID: 34155348 DOI: 10.1038/s41388-021-01889-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
70 Dowling CM, Zhang H, Chonghaile TN, Wong KK. Shining a light on metabolic vulnerabilities in non-small cell lung cancer. Biochim Biophys Acta Rev Cancer 2021;1875:188462. [PMID: 33130228 DOI: 10.1016/j.bbcan.2020.188462] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
71 Shimada A, Ueno H, Inagaki M. Glutaminase inhibitory activities of pentacyclic triterpenes isolated from Thymus vulgaris L. Nat Prod Res 2021;:1-5. [PMID: 33957830 DOI: 10.1080/14786419.2021.1921766] [Reference Citation Analysis]
72 Wei Z, Liu X, Cheng C, Yu W, Yi P. Metabolism of Amino Acids in Cancer. Front Cell Dev Biol 2020;8:603837. [PMID: 33511116 DOI: 10.3389/fcell.2020.603837] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
73 Momcilovic M, Bailey ST, Lee JT, Fishbein MC, Braas D, Go J, Graeber TG, Parlati F, Demo S, Li R, Walser TC, Gricowski M, Shuman R, Ibarra J, Fridman D, Phelps ME, Badran K, St John M, Bernthal NM, Federman N, Yanagawa J, Dubinett SM, Sadeghi S, Christofk HR, Shackelford DB. The GSK3 Signaling Axis Regulates Adaptive Glutamine Metabolism in Lung Squamous Cell Carcinoma. Cancer Cell 2018;33:905-921.e5. [PMID: 29763624 DOI: 10.1016/j.ccell.2018.04.002] [Cited by in Crossref: 70] [Cited by in F6Publishing: 69] [Article Influence: 23.3] [Reference Citation Analysis]
74 Ivy SP, Kunos CA, Arnaldez FI, Kohn EC. Defining and targeting wild-type BRCA high-grade serous ovarian cancer: DNA repair and cell cycle checkpoints. Expert Opin Investig Drugs 2019;28:771-85. [PMID: 31449760 DOI: 10.1080/13543784.2019.1657403] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
75 Mendes C, Serpa J. Metabolic Remodelling: An Accomplice for New Therapeutic Strategies to Fight Lung Cancer. Antioxidants (Basel) 2019;8:E603. [PMID: 31795465 DOI: 10.3390/antiox8120603] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
76 Momcilovic M, Shackelford DB. Dual targeting of EGFR and glutaminase in lung cancer. Mol Cell Oncol 2018;5:e1297883. [PMID: 30250881 DOI: 10.1080/23723556.2017.1297883] [Reference Citation Analysis]